Petronella O Witteveen
Overview
Explore the profile of Petronella O Witteveen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1706
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brink G, Groeneweg J, Sickinghe A, Nijman H, van Lonkhuijzen L, Lok C, et al.
J Ovarian Res
. 2025 Feb;
18(1):37.
PMID: 39987174
Background: As current literature does not provide sufficient data to support clear guidelines in patients with a rare adult-type granulosa cell tumor, we aim to investigate: (1) whether additional staging...
2.
Brink G, Hami N, Mertens S, Nijman H, van Lonkhuijzen L, Roes E, et al.
Mol Cancer Ther
. 2024 Nov;
PMID: 39600124
In patients with the rare adult-type granulosa cell tumors (aGCT), surgery is the primary treatment for both primary and recurrent disease. In cases of inoperable disease, systematic therapy is administered,...
3.
Koldenhof J, Akpobome B, Zweers D, Klaasse S, Teunissen S, Witteveen P, et al.
J Patient Rep Outcomes
. 2024 Oct;
8(1):120.
PMID: 39422800
Introduction: The Utrecht Symptom Diary (USD) is a validated Dutch patient-reported outcome measurement (PROM) tool - based on the Edmonton Symptom Assessment System - to assess and monitor symptoms in...
4.
Luijten M, Van Weelden W, Lalisang R, Bulten J, Lindemann K, van Beekhuizen H, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893205
Background: Response to hormonal therapy in advanced and recurrent endometrial cancer (EC) can be predicted by oestrogen and progesterone receptor immunohistochemical (ER/PR-IHC) expression, with response rates of 60% in PR-IHC...
5.
Westermann A, Ottevanger P, Reyners A, Kroep J, van Oijen M, Lalisang R, et al.
Int J Gynecol Cancer
. 2024 Jan;
34(2):239-243.
PMID: 38184318
Objective: There is a continued need for improvement of second-line systemic treatment for metastatic and/or recurrent endometrial cancer. Methods: In this phase II, open-label study, eligible patients had histologically or...
6.
Embaby A, Kutzera J, Geenen J, Pluim D, Hofland I, Sanders J, et al.
Gynecol Oncol
. 2023 May;
174:239-246.
PMID: 37236033
Objective: In the first part of this phase II study (NCT01164995), the combination of carboplatin and adavosertib (AZD1775) was shown to be safe and effective in patients with TP53 mutated...
7.
Brink G, Groeneweg J, Hooft L, Zweemer R, Witteveen P
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740663
For adult granulosa cell tumors (aGCTs), the preferred treatment modality is surgery. Chemotherapy and anti-hormonal therapy are also frequently used in patients with recurrent aGCT. We aimed to review the...
8.
Bruijnen C, Koldenhof J, Verheijden R, van den Bos F, Emmelot-Vonk M, Witteveen P, et al.
Cancer
. 2022 Apr;
128(14):2746-2752.
PMID: 35439334
Background: Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs) that range from mild to life-threatening. Age itself does not seem to be a predictor for the occurrence of...
9.
de Witte C, Kutzera J, Van Hoeck A, Nguyen L, Boere I, Jalving M, et al.
Cancers (Basel)
. 2022 Mar;
14(6).
PMID: 35326660
The majority of patients with ovarian cancer ultimately develop recurrent chemotherapy-resistant disease. Treatment stratification is mainly based on histological subtype and stage, prior response to platinum-based chemotherapy, and time to...
10.
Koldenhof J, van der Baan F, Verberne E, Kamphuis A, Verheijden R, Tonk E, et al.
J Pain Symptom Manage
. 2022 Feb;
63(6):997-1005.
PMID: 35196557
Context: While praised for inducing durable anti-tumour responses, immune checkpoint inhibitors (ICI) also cause immune-related adverse events (irAEs) that can vary in severity and affect health-related quality of life (HRQL)....